Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 26;14(11):2350.
doi: 10.3390/v14112350.

Sustained Virologic Suppression Reduces HIV-1 DNA Proviral Levels and HIV Antibodies in Perinatally HIV-Infected Children Followed from Birth

Affiliations

Sustained Virologic Suppression Reduces HIV-1 DNA Proviral Levels and HIV Antibodies in Perinatally HIV-Infected Children Followed from Birth

Trevon Fuller et al. Viruses. .

Abstract

The extent to which perinatally HIV-infected children, following cART initiation, develop a low proviral reservoir burden over time, as measured by HIV DNA droplet-digital polymerase chain reaction (ddPCR) and the effect on HIV antibody is not well characterized. We measured proviral HIV DNA and plasma RNA virus load (VL) in 37 perinatally HIV-infected children at 6 months of age who initiated stable cART. At 6-11 years of age, HIV proviral DNA, HIV VL (RNA), and HIV antibody by Western Blot (WB) were assessed. CART was initiated before 6 months of age in 13 children and after 6 months in 24. At school age, the HIV DNA levels did not differ by the timing of cART, and the HIV DNA levels were lower in children with negative/indeterminate WB (p = 0.0256). Children with undetectable HIV RNA VL > 50% of the time since cART initiation had lower median DNA VL than children with undetectable VL < 50% of the time (p = 0.07). Long-term viral suppression in perinatally HIV-infected children is associated with a decrease in HIV antibodies and reduced HIV reservoirs.

Keywords: HIV DNA droplet digital PCR; early HIV treatment; perinatal HIV infection; viral load kinetics; viral reservoir burden.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Flowchart of children living with HIV enrolled in the present study.
Figure 2
Figure 2
Kaplan–Meier survival curves indicating the effect of cART initiation on time to virologic suppression of HIV RNA (N = 37). In total 13 infants initiated cART at up to 6 months of life, and 24 after 6 months. There were 4 children who never achieved undetectable VL after starting cART.
Figure 3
Figure 3
Virologic and immunologic endpoints by time of treatment initiation. (A) HIV RNA VL at 6 months of age (N = 33); (B) HIV DNA ddPCR at 6 months of age (N = 32); (C) HIV RNA VL at 6–11 years of age (N = 37); (D) HIV DNA ddPCR at 6–11 years of age (N = 35).
Figure 4
Figure 4
HIV RNA viral load kinetics according to response to therapy status. (A) Complete responders (N = 15) children with an undetectable VL at study entry with HIV RNA viral loads undetectable more than 75% of the time since cART initiation in early childhood. The dashed red line depicts the child’s age at cART initiation. (B) Partial Responders (N = 8), children with an undetectable VL at study entry with undetectable HIV RNA VL between 50–75% of the time since cART initiation in early childhood. (C) Non-responders (N = 14), children with detectable HIV RNA VL at study entry and/or HIV RNA VL detectable up to 50% of the time since cART initiation in early childhood.
Figure 5
Figure 5
Viral reservoirs during childhood (6–11 years of age) measured by HIV DNA ddPCR. (A) HIV DNA ddPCR according to HIV-1 Western blot results; (B) HIV DNA ddPCR results according to response to cART; One child classified as a responder based on HIV RNA did not have ddPCR available, and 1 classified by HIV RNA as a non-responder did not have ddPCR.

References

    1. UNAIDS . Confronting Inequalities: Lessons for Pandemic Responses from 40 Years of AIDS. UNAIDS; Geneva, Switzerland: 2021.
    1. McManus M., Henderson J., Gautam A., Brody R., Weiss E.R., Persaud D., Mick E., Luzuriaga K., Investigators P. Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate with Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy. Clin. Infect. Dis. 2018;68:1725–1732. doi: 10.1093/cid/ciy753. - DOI - PMC - PubMed
    1. Rocca S., Zangari P., Cotugno N., De Rossi A., Ferns B., Petricone D., Rinaldi S., Giaquinto C., Bernardi S., Rojo P., et al. Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. J. Pediatr. Infect. Dis. Soc. 2018;8:433–438. doi: 10.1093/jpids/piy080. - DOI - PMC - PubMed
    1. Veldsman K.A., Laughton B., Janse van Rensburg A., Zuidewind P., Dobbels E., Barnabas S., Fry S., Cotton M.F., van Zyl G.U. Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age. AIDS. 2021;35:1247–1252. doi: 10.1097/QAD.0000000000002861. - DOI - PMC - PubMed
    1. Deeks S.G. Towards an HIV cure: A global scientific strategy. Nat. Rev. Immunol. 2012;12:607–614. doi: 10.1038/nri3262. - DOI - PMC - PubMed

Publication types